AI is reshaping the medical device landscape at a pace that few could have predicted. For strategic buyers, investors, and device manufacturers, AI is no longer an optional enhancement – it is becoming the core value driver in transactions. As deal activity accelerates in digital health and connected devices, understanding how the presence of AI changes diligence, risk allocation, and regulatory strategy is critical to executing successful M&A.

AI-enabled devices introduce unique diligence considerations that go well beyond a traditional software review. Buyers now need to closely examine the origins of training data, model development and validation processes, cybersecurity posture, data use and distribution practices, and ongoing performance monitoring. Each of those considerations present distinct regulatory, IP, and patient-safety risks. FDA's evolving approach to AI/ML-enabled medical devices adds yet another dimension: companies must demonstrate that their technology not only performs safely today, but can be updated, monitored, and controlled responsibly over time. This means diligence now regularly includes examination of ML lifecycle documentation, adaptive and predetermined change control systems, and evidence supporting claims of transparency, explainability, and bias mitigation.

FDA regulation is also reshaping deal strategy and valuation. The agency's recent push toward real-world performance monitoring, transparency in model updates, and greater scrutiny of adaptive algorithms is fundamentally changing how acquirers assess regulatory readiness. FDA expects manufacturers to maintain clear evidence of model training methods, human factors considerations, cybersecurity safeguards, and defined post market control plans. These requirements can materially affect deal timelines and integration planning. Acquirers are increasingly demanding detailed AI governance frameworks to ensure that a target's technology aligns with FDA's expectations for predictability, risk management, and continuous oversight. Companies that can show a clear, credible FDA pathway and a strong compliance culture often command premium valuations.

From a transactional standpoint, we are seeing a shift in how parties negotiate and distribute risk. Representations and warranties tied to data rights, algorithm integrity, and regulatory compliance are becoming more detailed – and more consequential. Earn-outs tied to AI performance milestones are increasingly common, reflecting both the promise and unpredictability of emerging models. At the same time, sellers with mature AI governance frameworks and clear FDA pathways are commanding higher valuations, demonstrating that structure and discipline in AI development directly translate to deal value.

Looking forward, the convergence of AI capabilities, remote monitoring, wearable technologies, and consumer wellness technologies will continue to fuel cross-sector M&A. Companies able to integrate regulatory readiness, strong data stewardship, and continuous model oversight will be best positioned to capitalize on the emerging growth opportunities and potential for premium valuations in the AI medical device sector.